eDiagnosis(SZ:002932) Sou Hu Cai Jing·2025-05-07 09:02Company Overview - Mingde Biological Technology Co., Ltd. primarily engages in the research, development, production, sales, and service of in vitro diagnostic reagents and diagnostic instruments [1] - The company's main products and services cover three major areas: in vitro diagnostic reagents and instruments, critical care information solutions, and third-party medical testing services [1] Financial Performance - As of Q1 2025, the company reported operating revenue of 69.96 million yuan, representing a year-on-year increase of 14.76% [1] - The net profit for the same period was -3.66 million yuan, reflecting a year-on-year decline of 111.43% [1] - The gross profit margin stood at 16.37% [1] Market Position - The company's closing stock price on May 7 was 18.72 yuan, down 1.58%, with a rolling price-to-earnings (PE) ratio of 112.17 times [1] - The total market capitalization is 4.353 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 49.02 times, with a median of 36.25 times, placing Mingde Biological at the 107th position in the industry ranking [1][2] Shareholder Information - As of March 31, 2025, the number of shareholders was 25,981, a decrease of 717 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1] Industry Recognition - In December 2022, a hospital in Hubei Province utilizing the company's information solutions won the Best Solution Award for Smart Chest Pain Center at the China Cardiovascular Health Conference, marking it as the only county-level hospital to receive this award [1]